Certificate Under Regulation 40(9) Of The SEBI Listing Regulations For The QE Dec 2017
Subject: Certificate under Regulation 40(9) of the SEBI Listing Regulations. With reference to the above we are enclosing herewith Certificate under Regulation 40(9) of the SEBI Listing Regulations for the period ended 31st December 2017. Kindly acknowledge receipt. Thanking you, Yours faithfully, For MERCK LIMITED Vikas R. Gupta General Counsel & Company Secretary Statement Of Investor Grievance Report For The Quarter Ended December 2017
Subject: Quarterly Investor Grievance Report as per Reg. 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the above we are enclosing herewith quarterly investor grievance report as per Reg. 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31st December 2017. Kindly acknowledge receipt. Thanking you, Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India Toasts to the Deals (and Other Winners) of 2017
Some CEOs on Trump's councils such as Kenneth C Frazier of Merck rebuked the president's comments after the Charlottesville violence Merck phase 3 KEYNOTE061study of antiPD1 therapy, Keytruda to treat advanced GEJ fails to meet endpoints
Merck, known as MSD outside the United States and Canada, announced that the pivotal phase 3 KEYNOTE061 trial investigating Keytruda (pembrolizumab), the company's antiPD1 therapy, as a secondline treatment Updates
This is for the information of all concerned that the Company has issued the notice on December 13, 2017 to close its trading window due to year end results for the year ending December 31, 2017. Please note that the Company vide earlier notification dated September 05, 2017 to its employees had closed trading window due to Merck KGaA, the ultimate holding company of the Company had announced that it is preparing strategic options for its Consumer... Resignation of Managing Director
Sub: Intimation under Regulation 30 of the SEBI Listing Regulations. This is for the information of all concerned that Mr. Anand Nambiar, the Managing Director of the Company, has been offered a new assignment as 'Head of the Integrated Circuit Materials' business unit within Merck KGaA's Performance Materials Business at Darmstadt, Germany. Anand has accepted the same.... Merck, Pfizer announce phase III JAVELIN Gastric 300 trial in patients with pretreated advanced gastric cancer fails to meet primary endpoint
Merck and Pfizer have announced that the phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of superior overall survival (OS) with singleagent avelumab compared with physician's choice of